A Randomized, Double-Blind Placebo-Controlled, Phase 3 Study of Debio 1143 in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy (TrilynX)
Larynx | Lip, Oral Cavity and Pharynx
What is the purpose of this trial?
The primary objective of the study is to demonstrate superior efficacy of Debio 1143 vs placebo when added to chemoradiotherapy (CRT) in locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN).
- Ages18 years and older
- Trial withEMD Serono, Inc.
- Start Date05/18/2022
- End Date12/01/2024
- Last Updated09/28/2022
- Study HIC#2000029690